Under the agreement, VECOL will act as the primary implementing partner while SK bioscience contributes technology transfer and manufacturing support.
The initial product involved is SKYVaricella, SK bioscience’s varicella vaccine, with plans for broader portfolio expansion in future. Credit: SK bioscience.
SK bioscience has signed a vaccine technology transfer and manufacturing agreement with Colombia’s state-owned pharmaceutical company VECOL, becoming part of the country’s $260m vaccine localisation initiative.
This move strengthens vaccine supply resilience in Colombia and creates a pathway for SK bioscience’s expansion into Latin America. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
